8.99

2.55% -0.22

Immunome Inc (IMNM)

Overview News Price History Option Chain Financials Discussions Forecast

Immunome Inc stock is traded at $8.99, with a volume of 122.00K. It is down -2.55% in the last 24 hours and down -13.95% over the past month. Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.

Previous Close:

$9.21

Open:

$9.37

24h Volume:

122.00K

Relative Volume:

0.14

Market Cap:

$781.97M

Revenue:

Net Income/Loss:

$-106.81M

P/E Ratio:

-2.7146

EPS:

-3.3117

Net Cash Flow:

$-8.40M

1W Performance:

-2.66%

1M Performance:

-13.95%

6M Performance:

-43.80%

1Y Performance:

-62.13%

1-Day Range:

$8.97

$9.49

1-Week Range:

$8.385

$9.53

52-Week Range:

$8.385

$26.70

Immunome Inc Stock (IMNM) Company Profile

Name

Immunome Inc

Sector

Healthcare (1172)

Industry

Biotechnology (680)

Phone

610-321-3700

Address

18702 N. CREEK PARKWAY, BOTHELL

Employee

105

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

IMNM's Discussions on Twitter

Compare IMNM with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IMNM Immunome Inc	8.97	781.97M	0	-106.81M	-8.40M	-3.3117
VRTX Vertex Pharmaceuticals Inc	499.31	130.96B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	678.13	75.53B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	577.05	35.07B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	240.71	31.72B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	249.10	26.76B	3.32B	-860.46M	-1.04B	-8.32

Immunome Inc Stock (IMNM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-08-24	Initiated	Stephens	Overweight
May-31-24	Initiated	Piper Sandler	Overweight
Apr-30-24	Initiated	JP Morgan	Overweight
Apr-15-24	Initiated	Guggenheim	Buy
Jan-29-24	Initiated	Leerink Partners	Outperform
Dec-19-23	Initiated	Wedbush	Outperform
Oct-29-21	Initiated	Cantor Fitzgerald	Overweight

View All

Immunome Inc Stock (IMNM) Latest News

Mar 12, 2025

Immunome (NASDAQ:IMNM) Now Covered by Lifesci Capital - Defense World

Mar 12, 2025

Mar 11, 2025

LifeSci Capital Initiates Coverage of Immunome (IMNM) with Outperform Recommendation - Nasdaq

Mar 11, 2025

Immunome’s (IMNM) “Outperform” Rating Reaffirmed at Wedbush - Defense World

Mar 11, 2025

Mar 10, 2025

Immunome stock hits 52-week low at $8.53 amid market challenges - Investing.com India

Mar 10, 2025

Immunome doses first patient in early-stage trial of its experimental cancer treatment -March 10, 2025 at 08:23 am EDT - Marketscreener.com

Mar 10, 2025

Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC - Joplin Globe

Mar 10, 2025

Immunome Doses First Patient in Phase 1 Cancer Drug Trial - StockTitan

Mar 10, 2025

Mar 06, 2025

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 6, 2025 - BioSpace

Mar 06, 2025

Immunome's Latest Talent Investment: 49,000 Share Options Awarded to Key New Hires - StockTitan

Mar 06, 2025

Feb 28, 2025

Immunome (NASDAQ:IMNM) Sets New 52-Week LowHere's Why - MarketBeat

Feb 28, 2025

Immunome, Inc. (NASDAQ:IMNM) Shares Sold by Handelsbanken Fonder AB - MarketBeat

Feb 28, 2025

Long Term Trading Analysis for (IMNM) - Stock Traders Daily

Feb 28, 2025

Feb 25, 2025

Immunome stock hits 52-week low at $8.97 amid market challenges By Investing.com - Investing.com South Africa

Feb 25, 2025

Immunome stock hits 52-week low at $8.97 amid market challenges - Investing.com India

Feb 25, 2025

Three Bridge Wealth Advisors LLC Invests $293,000 in Immunome, Inc. (NASDAQ:IMNM) - MarketBeat

Feb 15, 2025

Immunome (NASDAQ:IMNM) Trading Down 6.7%Should You Sell? - MarketBeat

Feb 15, 2025

Feb 14, 2025

Immunome (NASDAQ:IMNM) Trading Up 11.7%Here's What Happened - MarketBeat

Feb 14, 2025

Q1 Earnings Forecast for Immunome Issued By Leerink Partnrs - MarketBeat

Feb 14, 2025

Feb 11, 2025

Immunome (NASDAQ:IMNM) Stock Price Down 6.7% – Here’s What Happened - Defense World

Feb 11, 2025

Philadelphia biotech firm backed by more than $130M names new CEO - The Business Journals

Feb 11, 2025

Pharma Veteran Behind Immunome's Success Story Named CEO of Rising Biotech Aro - StockTitan

Feb 11, 2025

Research Analysts Set Expectations for Immunome Q1 Earnings - Defense World

Feb 11, 2025

Feb 10, 2025

Checking in on Immunome Inc (IMNM) after recent insiders movement - Knox Daily

Feb 10, 2025

Feb 08, 2025

After The Stock Fell -1.45% Over The Week, Is Immunome Inc (NASDAQ: IMNM) Still A Buy? - Marketing Sentinel

Feb 08, 2025

Immunome, Inc. (NASDAQ:IMNM) CEO Clay B. Siegall Purchases 150,000 Shares - MarketBeat

Feb 08, 2025

Short Interest in Immunome, Inc. (NASDAQ:IMNM) Rises By 12.2% - MarketBeat

Feb 08, 2025

Feb 06, 2025